Literature DB >> 6421974

Spur cells in patients with alcoholic liver cirrhosis are associated with reduced plasma levels of apoA-II, HDL3, and LDL.

G Duhamel, P Forgez, B Nalpas, P Berthelot, M J Chapman.   

Abstract

The precise nature and origin(s) of the abnormalities in lipoprotein and apolipoprotein profile associated with severe hepatic dysfunction and the presence of spur cells remain poorly defined. To shed light on this question, we have analyzed the plasma lipoprotein and apolipoprotein profiles in five patients with alcoholic cirrhosis and spur cells, and compared them with those of a group with similar hepatocellular dysfunction, but lacking spur cells, and with that of a control group. Lipoproteins were subfractionated by density gradient ultracentrifugation and their physicochemical properties were determined; apolipoprotein A-I, A-II, and B contents in plasma and the respective subfractions were quantitated by radial immunodiffusion, while the complement of low molecular weight apolipoproteins in each subfraction was analyzed by isoelectric focusing and electrophoresis in alkaline-urea polyacrylamide gels. Spur cell plasma was distinguished by reduced levels of apoA-II and elevated ratios of apoA-I/apoA-II (approximately 13:1 as compared to 3.3-3.9:1 in the other two groups), and by reduced concentrations of HDL3. Gradient fractionation showed the apoA-II content of HDL3 to be dramatically and significantly diminished in spur cell plasma; in addition, apoA-II content was reduced relative to apoA-I in this subclass (4.7:1 as compared to 1:1 in cirrhotics lacking spur cells and 1.9:1 in controls). Spur cell HDL2 was similarly deficient in apoA-II, with elevated ratios of apoA-I:apoA-II (9.8:1 in comparison with 1.9-2.5:1 in the two other groups). Nonetheless, high HDL2 concentrations were seen in both series of cirrhotic patients, irrespective of red cell morphology. Spur cell HDL2 thus appears to consist primarily of particles possessing only apoA-I, with a minor population containing both apoA-I and apoA-II. The free cholesterol content of all lipoprotein subfractions from spur cell plasma was increased, as indeed was the molar ratio of free cholesterol to phospholipid, in comparison with that of corresponding fractions from alcoholic cirrhotics lacking spur cells and of control subjects. LDL levels were reduced in spur cell plasma, thereby distinguishing this group from the cirrhotics without spur cells who displayed elevated LDL levels. Markedly reduced plasma levels of apoA-II, HDL3, and LDL appear characteristic of alcoholic cirrhotics presenting with spur cells. Our findings suggest that apoA-II may be essential to the normal function and metabolism of HDL, one aspect of which may be the transport of free cholesterol and thereby the direct or indirect maintenance of red cell morphology.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6421974

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  5 in total

Review 1.  Abnormalities of Lipoprotein Levels in Liver Cirrhosis: Clinical Relevance.

Authors:  Graziella Privitera; Luisa Spadaro; Simona Marchisello; Giuseppe Fede; Francesco Purrello
Journal:  Dig Dis Sci       Date:  2017-11-25       Impact factor: 3.199

2.  Antioxidative status of patients with alcoholic liver disease in southeastern Taiwan.

Authors:  Ya-Ling Chen; Li-Ju Chen; Ming-Jong Bair; Mei-Lan Yao; Hsiang-Chi Peng; Sien-Sing Yang; Suh-Ching Yang
Journal:  World J Gastroenterol       Date:  2011-02-28       Impact factor: 5.742

3.  An unusual cause of anemia in cirrhosis: spur cell anemia, a case report with review of literature.

Authors:  Graziella Privitera; Giovanni Meli
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2016

4.  The Diagnosis Is in the Smear: A Case and Review of Spur Cell Anemia in Cirrhosis.

Authors:  Gabriella A Raffa; Diana M Byrnes; John J Byrnes
Journal:  Case Rep Hematol       Date:  2021-03-26

5.  Plasmapheresis for Spur Cell Anemia in a Patient with Alcoholic Liver Cirrhosis.

Authors:  Kenji Miki; Takashi Maruki; Shinsaku Imashuku
Journal:  Case Rep Hematol       Date:  2018-06-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.